<DOC>
	<DOCNO>NCT02236715</DOCNO>
	<brief_summary>Study obtain information tolerability efficacy Atrovent® unit dose vial 500 µg treatment Chronic Obstructive Airways Disease condition daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study Atrovent® Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Primarily patient gender , old 30 year , suffer chronic obstructive airway disease Only patient treat Atrovent® within last year consider inclusion Contraindication list instruction use/summary product characteristic Atrovent® unit dose vial 500 µg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>